Document:

rptx-ex44_737.htm

 

Exhibit 4.4

 

DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF

THE SECURITIES EXCHANGE ACT OF 1934 

The following description of the common shares of Repare Therapeutics Inc., a corporation organized under the Business Corporations Act (Québec), or the Company, is a summary and does not purport to be complete. This summary is qualified in its entirety by reference to the provisions of Québec law, and the complete text of the Company’s articles of continuance and amended and restated bylaws, which are incorporated by reference as Exhibits 3.1 and 3.2, respectively, of the Company’s Annual Report on Form 10-K to which this description is also an exhibit. The Company encourages you to read that law and those documents carefully.

General

The Company’s share capital consists of an unlimited number of common shares, no par value per share, and an unlimited number of preferred shares, no par value per share.

Description of Common Shares

Voting Rights

Under the Company’s articles of continuance, the holders of common shares are entitled to one vote for each share held at any meeting of the shareholders.

Dividends

Subject to preferences that may be applicable to any then-outstanding preferred shares, the holders of common shares are entitled to receive dividends as and when declared by the Company’s board of directors.

Liquidation

Subject to payments that may be payable to the holders of any then-outstanding preferred shares, in the event of the Company’s liquidation, dissolution or winding-up or other distribution of its assets among the Company’s shareholders, the holders of common shares are entitled to share pro rata in the distribution of the balance of the Company’s assets.

Rights and Preferences

The holders of common shares have no preemptive, conversion rights or other subscription rights. There are no redemption or sinking fund provisions applicable to the Company’s common shares. There is no provision in the Company’s articles of continuance requiring the holders of common shares to contribute additional capital or permitting or restricting the issuance of additional securities or any other material restrictions. The rights, preferences and privileges of the holders of common shares are subject to and may be adversely affected by, the rights of the holders of any series of preferred shares that the Company may designate in the future.

Registration Rights

Certain holders of the Company’s common shares are entitled to certain rights with respect to registration of such shares under the Securities Act of 1933, as amended, or the Securities Act, pursuant to the terms of a certain registration rights agreement by and among the Company and certain shareholders. Such shares are referred to as registrable securities. The registration of common shares pursuant to the exercise of the registration rights described below would enable the holders to trade these shares without restriction under the Securities Act when the applicable registration statement is declared effective. The registration rights under this registration rights agreement will expire no later than June 23, 2023, or with respect to any particular holder, at such time that such holder can sell its shares under Rule 144 of the Securities Act during any three-month period.

 

 

The Company will pay the registration expenses, other than underwriting fees, selling commissions and share transfer taxes, of the shares registered pursuant to such registration rights. Expenses relating to underwriting fees, selling commissions and share transfer taxes for the shares registered will be borne by the Company and the participating holders in proportion to the number of common shares sold by each, or, as between the participating holders, as such participating holders may otherwise agree.

The registration rights agreement contains customary cross-indemnification provisions, pursuant to which the Company is obligated to indemnify the selling shareholders in the event of material misstatements or omissions in the registration statement attributable to the Company, and the selling shareholders are obligated to indemnify the Company for material misstatements or omissions in the registration statement attributable to them.

Choice of Forum

The Company’s amended and restated bylaws provide that the courts of the Province of Québec and the appellate courts therefrom shall, to the fullest extent permitted by law, be the sole and exclusive forum for: (i) any derivative action or proceeding brought on the Company’s behalf; (ii) any action or proceeding asserting a claim for breach of a fiduciary duty owed to the Company by any of its directors, officers or other employees; (iii) any action or proceeding asserting a claim arising pursuant to any provision of the Business Corporations Act (Québec) or the Company’s articles or by-laws (as either may be amended from time to time); or (iv) any action or proceeding asserting a claim otherwise related to the Company’s affairs, provided that, the exclusive forum provision does not apply to suits brought to enforce any liability or duty created by the Securities Act, the Securities Exchange Act of 1934, as amended, or any other claim for which the U.S. federal courts have exclusive jurisdiction. The Company’s amended and restated bylaws further provide that unless the Company consents in writing to the selection of an alternative forum, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. It is possible that a court of law could rule that the choice of forum provision contained in the Company’s amended and restated bylaws is inapplicable or unenforceable if it is challenged in a proceeding or otherwise. For example, under the Securities Act, federal courts have concurrent jurisdiction over all suits brought to enforce any duty or liability created by the Securities Act, and investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder.

Transfer Agent and Registrar

The transfer agent and registrar for the Company’s common shares is Computershare Investor Services Inc. The transfer agent’s address is 1500 Robert-Bourassa Boulevard, 7th Floor, Montréal, Québec H3A 3S8.

Nasdaq Global Select Market Listing

The Company’s common shares are listed on the Nasdaq Global Select Market under the symbol “RPTX.”

 

2rptx-ex1020_738.htm

Exhibit 10.20

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED.

 

 THIRD AMENDMENT
TO
COLLABORATION AND LICENSE AGREEMENT

This Third Amendment to Collaboration and License Agreement (this “Third Amendment”) is entered into as of November 30, 2020 (the “Third Amendment Effective Date”) by and between Repare Therapeutics Inc., a Canadian corporation with offices at 7210 Frederick- Banting, Suite 100, St. Laurent, Quebec, Canada H4S 2A1 (“Repare Inc.”) and Repare Therapeutics USA, Inc., a Delaware corporation with offices at One Broadway, 15th Floor, Cambridge, Massachusetts 02142 (“Repare USA” and, together with Repare Inc., “Repare”), on the one hand, and Bristol-Myers Squibb Company, a Delaware corporation with offices at 430 E. 29th Street, 14th Floor, New York, New York 10016 (“BMS”), on the other hand. BMS and Repare are each referred to herein by name or as a “Party”, or, collectively, as the “Parties.” 

WHEREAS, Repare and BMS entered into that certain Collaboration and License Agreement as of May 26, 2020 (as amended, the “Agreement”), pursuant to which, among other things, certain information and data is provided to the BMS members of the JSC on an unblinded basis; and 

WHEREAS, the Parties wish to amend the Agreement to enable unblinding of additional BMS employees as Firewalled Scientists in relation to the Undruggable Target referred to as [***] in the [***] Existing Repare Campaign (“Target X”);

WHEREAS, the Agreement does not address the identification of an Undruggable Target in an Existing Repare Campaign except through the Third Party Gatekeeper, and the Parties would like to amend the Agreement to agree how they will work together in relation to Target X.

NOW, THEREFORE, the Parties, intending to be legally bound, hereby agree as follows: 

	
 
	
1.
	
Capitalized terms used in this Third Amendment that are not defined herein shall have the meanings ascribed to them in the Agreement.

	
 
	
2.
	
The [***] lesion is an Existing Repare Campaign.  Following Initial Screening for such Existing Repare Campaign, Repare has identified Target X as showing promise for Synthetic Lethality as a Repare Potential Undruggable Target with respect to such [***] Existing Repare Campaign.

	
 
	
3.
	
Repare has provided to BMS information and data regarding Target X.  The identity of Target X has been unblinded [***] in accordance with the terms of the Agreement.  BMS has requested that Repare provide, and Repare has agreed to provide, such an unblinded information regarding Target X to the following individuals: [***] (the “Unblinded BMS Individuals”).  Each such individual will, from and after the Third Amendment Effective Date, be a Firewalled Scientist for purposes of the Agreement in relation to Target X.  

	
 
	
4.
	
Repare agrees that the Unblinded BMS Individuals will have the right to perform the activities described in the work plan attached as Schedule A hereto in relation to Target X (the “Permitted Target X Activities”).  For the avoidance of doubt, the Permitted Target X Activities will not constitute or be deemed to constitute Chemistry for purposes of the Agreement.

 

 

	
 
	
5.
	
The Parties agree that (a) Target X is an Undruggable Target, (b) the [***] Undruggable Target Unblinding Period in which BMS may deliver an Undruggable Target Unblinding Notification for Target X as set forth in Section 2.6.3(a) will start from the date of the JSC meeting that will be held after completion of the Permitted Target X Activities to discuss the results of such activities and (c) from and after the Third Amendment Effective Date, [***] shall be deemed to no longer be an Existing Repare Campaign (and, for the avoidance of doubt, shall not be either a Pre-Option Campaign or Collaboration Campaign).

	
 
	
6.
	
This Third Amendment shall be deemed incorporated into and made a part of the Agreement.  The provisions of this Third Amendment shall constitute an amendment to the Agreement, and, to the extent that any term or provision of this Third Amendment may be deemed expressly inconsistent with any term or provision in the Agreement, this Third Amendment shall govern and control.  Except as expressly modified by the terms of this Third Amendment, all of the terms, conditions, and provisions of the Agreement are hereby ratified, and the Agreement remains in full force and effect.

	
 
	
7.
	
This Third Amendment may be executed in two (2) counterparts, each of which shall be deemed an original, and both of which together shall constitute one and the same instrument.  Any such counterpart, to the extent delivered by means of electronic delivery, shall be treated in all manner and respects as an original executed counterpart and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person.  No Party hereto shall raise the use of electronic delivery to deliver a signature or the fact that any signature or agreement or instrument was transmitted or communicated through the use of electronic delivery as a claim or defense with respect to the formation of a contract, and each Party forever waives any such claim or defense, except to the extent that such claim or defense relates to lack of authenticity.

 

[Signature Page Follows]

 

 

 

 

IN WITNESS WHEREOF, and intending to be legally bound hereby, the Parties have caused this Third Amendment to Collaboration and License Agreement to be executed by their respective duly authorized officers as of the Third Amendment Effective Date.

 

	
BRISTOL-MYERS SQUIBB COMPANY

	
 

	
By:
	
 
	
 
	
 
	
/s/ Janeen Doyle

	
 
	
 
	
Name:
	
 
	
Janeen Doyle

	
 
	
 
	
Title:
	
 
	
VP, R&ED Alliances

Strategy and Business Development

	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 

	
REPARE THERAPEUTICS INC.

	
 

	
By:
	
 
	
 
	
 
	
/s/ Steve Forte

	
 
	
 
	
Name:
	
 
	
Steve Forte

	
 
	
 
	
Title:
	
 
	
EVP & CFO

	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 

	
REPARE THERAPEUTICS USA, INC.

	
 

	
By:
	
 
	
 
	
 
	
/s/ Kim A. Seth

	
 
	
 
	
Name:
	
 
	
Kim A. Seth

	
 
	
 
	
Title:
	
 
	
EVP, Head of Business

and Corporate Development

 

 

 

Schedule A

 

[***]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00323-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00323-of-00352.parquet"}]]